Edition:
India

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

96.29USD
20 Feb 2020
Change (% chg)

$-0.93 (-0.96%)
Prev Close
$97.22
Open
$97.05
Day's High
$97.09
Day's Low
$95.89
Volume
253,389
Avg. Vol
283,410
52-wk High
$99.82
52-wk Low
$74.97

Latest Key Developments (Source: Significant Developments)

Novartis CFO says does not believe in large M&A
Wednesday, 29 Jan 2020 

Jan 29 (Reuters) - Novartis AG ::CFO SAYS DOES NOT BELIEVE IN LARGE M&A.CEO SAYS KEY RISK THAT IMPACTS SHARES OF HEALTHCARE COMPANIES IS U.S. HEALTHCARE REFORM.CEO SAYS HAS DONE COST-CUTTING ACTIONS AT SANDOZ, DOES NOT ANTICIPATE ADDITIONAL MEASURES AT THIS TIME.  Full Article

Novartis Announces EU Approval Of MS Drug Mayzent For Certain Adult Patients
Monday, 20 Jan 2020 

Jan 20 (Reuters) - Novartis AG ::NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR ADULT PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) WITH ACTIVE DISEASE.APPROVAL IS BASED ON PHASE III EXPAND TRIAL.  Full Article

Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog
Monday, 13 Jan 2020 

Jan 12 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS OBTAINS LICENSE TO DEVELOP AND COMMERCIALIZE A NOVEL IL-2 ANALOG.OBTAINED A LICENSE FROM NOVARTIS TO DEVELOP AND COMMERCIALIZE AN ANTIBODY CYTOKINE ENGRAFTED PROTEIN, REFERRED TO AS IOV-3001.NOVARTIS IS ALSO ENTITLED TO LOW-TO-MID SINGLE DIGIT ROYALTIES FROM COMMERCIAL SALES OF PRODUCT.UNDER AGREEMENT, CO WILL PAY AN UPFRONT PAYMENT TO NOVARTIS AS WELL AS LOW SINGLE DIGIT MILESTONES.  Full Article

Novartis Completes Tender Offer For All Outstanding Shares Of The Medicines Co.
Monday, 6 Jan 2020 

Jan 6 (Reuters) - Novartis AG ::REG-NOVARTIS COMPLETES TENDER OFFER FOR ALL OUTSTANDING SHARES OF THE MEDICINES COMPANY.NOVARTIS WILL PROMPTLY COMPLETE ITS ACQUISITION OF COMPANY.FOLLOWING MERGER, COMPANY WILL BE AN INDIRECT WHOLLY-OWNED SUBSIDIARY OF NOVARTIS.  Full Article

Novartis To Acquire The Medicines Company For $9.7 bln
Monday, 25 Nov 2019 

Nov 24 (Reuters) - Novartis Ag ::REG-NOVARTIS TO ACQUIRE THE MEDICINES COMPANY FOR USD 9.7 BN, ADDING INCLISIRAN, A POTENTIALLY TRANSFORMATIONAL INVESTIGATIONAL CHOLESTEROL-LOWERING THERAPY TO ADDRESS LEADING GLOBAL CAUSE OF DEATH.OFFER PRICE OF USD 85.00 PER SHARE.NOVARTIS - DEAL EXPECTED TO MODESTLY DILUTE CORE EPS VERSUS A NO DEAL SCENARIO DURING NEXT FEW YEARS AS CO INVESTS FOR A SUCCESSFUL LAUNCH OF INCLISIRAN.TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES.NOVARTIS PLANS TO FINANCE TRANSACTION THROUGH AVAILABLE CASH AND SHORT- AND LONG-TERM BORROWINGS.TRANSACTION IS EXPECTED TO CLOSE IN Q1 OF 2020, SUBJECT TO SATISFACTION OR WAIVER OF ALL CLOSING CONDITIONS.NOVARTIS - EXPECTS DEAL TO BE SIGNIFICANTLY ACCRETIVE TO GROUP CORE OPERATING INCOME AND CORE EPS IN MEDIUM TERM.ASSUMING COMPLETION IN Q1 OF 2020, CO EXPECTS INCLISIRAN TO START TO CONTRIBUTE TO GROUP AND IM DIVISION SALES FROM 2021.  Full Article

FDA Says Approves Novartis' Sickle Cell Disease Treatment Adakveo 100 Mg/10 Ml Injection
Saturday, 16 Nov 2019 

Nov 15 (Reuters) - U.S. FDA::FDA SAYS APPROVES NOVARTIS' SICKLE CELL DISEASE TREATMENT ADAKVEO 100 MG/10 ML INJECTION.  Full Article

Novartis Says New Medicine Adakveo® (Crizanlizumab) Approved By FDA
Saturday, 16 Nov 2019 

Nov 16 (Reuters) - Novartis AG ::REG-NEW NOVARTIS MEDICINE ADAKVEO® (CRIZANLIZUMAB) APPROVED BY FDA TO REDUCE FREQUENCY OF PAIN CRISES IN INDIVIDUALS LIVING WITH SICKLE CELL DISEASE.MEDICINE IS EXPECTED TO BE AVAILABLE TO PATIENTS IN COMING WEEKS.  Full Article

Vectura Says UK Court Dismissed GSK's Claims Of Passing Off In Respect Of Sandoz's Airflusal Forspiro
Friday, 4 Oct 2019 

Oct 4 (Reuters) - Vectura Group PLC ::VECTURA GROUP PLC - UK COURT RULING IN GSK V SANDOZ PASSING OFF CASE.VECTURA GROUP PLC - ENGLISH HIGH COURT HAS DISMISSED ALL OF GSK'S CLAIMS OF PASSING OFF IN RESPECT OF SANDOZ'S AIRFLUSAL FORSPIRO.  Full Article

Novartis Says Phase III PREVENT Study Met Primary Endpoint For Patients With Axial Spondyloarthritis
Tuesday, 17 Sep 2019 

Sept 17 (Reuters) - Novartis AG ::NOVARTIS COSENTYX® POSITIVE 16-WEEK PREVENT RESULTS ADVANCE POTENTIAL NEW INDICATION FOR PATIENTS WITH AXIAL SPONDYLOARTHRITIS.PHASE III PREVENT STUDY MET 16-WEEK PRIMARY ENDPOINT OF ASAS40 IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA).ALL SECONDARY ENDPOINTS WERE ALSO MET.NOVARTIS HAS SUBMITTED TO EMA FOR APPROVAL IN NR-AXSPA, WHICH WOULD BE FOURTH INDICATION FOR COSENTYX.52-WEEK DATA FROM PREVENT STUDY, TO SUPPORT FDA SUBMISSION, ARE EXPECTED LATER IN YEAR.  Full Article

Amplyx Pharmaceuticals Executed Exclusive Worldwide License Agreement With Novartis
Monday, 16 Sep 2019 

Sept 16 (Reuters) - Novartis AG ::AMPLYX PHARMACEUTICALS - EXECUTED EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH NOVARTIS.AMPLYX PHARMACEUTICAL - UNDER AGREEMENT CO ACQUIRED RIGHTS TO PHASE 2 ANTI-BK VIRUS MONOCLONAL ANTIBODY, MAU868, FOR TREATMENT, PREVENTION OF BKV DISEASE.AMPLYX PHARMACEUTICALS - FINANCIAL TERMS HAVE NOT BEEN DISCLOSED.  Full Article

BRIEF-Novartis Wins EC Approval For Anti-VEGF Treatment Beovu

* NOVARTIS RECEIVES EC APPROVAL FOR BEOVU®, A NEXT-GENERATION ANTI-VEGF TREATMENT FOR WET AMD, A LEADING CAUSE OF BLINDNESS WORLDWIDE